Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Lung cancer biomarkers: present status and future developments.

Lung cancer biomarkers: present status and future developments. The publication of the "Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology" has now provided a guideline for biomarker testing for first-generation lung cancer tyrosine kinase inhibitors. Biomarker testing has forever altered the role of pathologists in the management of patients with lung cancer. Current, unresolved issues in the precision medicine of lung cancer will be addressed by the development of new biomarker tests, new drugs, and new test technologies and by improvement in the cost to benefit ratio of biomarker testing. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of pathology & laboratory medicine Pubmed

Lung cancer biomarkers: present status and future developments.

Cagle, Philip T; Allen, Timothy Craig; Olsen, Randall J
Archives of pathology & laboratory medicine , Volume 137 (9): -1182 – Nov 14, 2013
Download PDF

Lung cancer biomarkers: present status and future developments.


Abstract

The publication of the "Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology" has now provided a guideline for biomarker testing for first-generation lung cancer tyrosine kinase inhibitors. Biomarker testing has forever altered the role of pathologists in the management of patients with lung cancer. Current, unresolved issues in the precision medicine of lung cancer will be addressed by the development of new biomarker tests, new drugs, and new test technologies and by improvement in the cost to benefit ratio of biomarker testing.

Loading next page...
 
/lp/pubmed/lung-cancer-biomarkers-present-status-and-future-developments-b2o2lXiW0c

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1543-2165
DOI
10.5858/arpa.2013-0319-CR
pmid
23991729

Abstract

The publication of the "Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology" has now provided a guideline for biomarker testing for first-generation lung cancer tyrosine kinase inhibitors. Biomarker testing has forever altered the role of pathologists in the management of patients with lung cancer. Current, unresolved issues in the precision medicine of lung cancer will be addressed by the development of new biomarker tests, new drugs, and new test technologies and by improvement in the cost to benefit ratio of biomarker testing.

Journal

Archives of pathology & laboratory medicine – Pubmed

Published: Nov 14, 2013

References

  • Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
    Lindeman
  • Cancer statistics, 2012
    Siegel
  • The international epidemiology of lung cancer: geographical distribution and secular trends
    Youlden
  • Revolution in lung cancer: new challenges for the surgical pathologist
    Cagle
  • Lung cancer and the future of pathology
    Cagle
  • Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification
    Travis
  • Diagnosis of lung adenocarcinoma in resected specimens: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification
    Travis
  • The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours
    Goldstraw
  • American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer
    Azzoli
  • 2011 focused update of 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer
    Azzoli
  • Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research
    Bonomi
  • Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis
    Delbaldo
  • Adjuvant chemotherapy for surgically resected non-small cell lung cancer
    Heon
  • Maintenance therapy in NSCLC: why? to whom? which agent
    Novello
  • A decade of advances in treatment of early-stage lung cancer
    Paoletti
  • Recent advances in non-small cell lung cancer biology and clinical management
    Saintigny
  • Epidermal growth factor receptor expression in human lung carcinomas defined by a monoclonal antibody
    Sobol
  • Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    Lynch
  • EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
    Paez
  • EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
    Pao
  • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    Mok
  • Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
    Mitsudomi
  • Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
    Maemondo
  • Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations
    Rekhtman
  • Lung cancer genotype-based therapy and predictive biomarkers: present and future
    Cagle
  • Targeted therapies in lung cancer
    Chirieac
  • Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities
    Gaughan
  • Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
    Soda
  • KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only
    Togashi
  • Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK
    Shaw
  • Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
    Shaw
  • Crizotinib and testing for ALK
    Shaw
  • The potential for crizotinib in non-small cell lung cancer: a perspective review
    Bang
  • Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers
    Katayama
  • Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
    Zhang
  • Adenosquamous carcinoma of the lung: a microdissection study of KRAS and EGFR mutational and amplification status in a Western patient population
    Tochigi
  • Are we missing the target: cancer stem cells and drug resistance in non-small cell lung cancer
    Gottschling
  • Non-small cell lung cancer
    Ettinger
  • International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma
    Travis
  • Biomarker analysis from completely resected NSCLC patients enrolled in an adjuvant erlotinib clinical trial (RADIANT)
    Richardson
  • Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations
    Janjigian
  • A multicenter phase II trial of adjuvant erlotinib in patients with resected non-small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR): toxicity evaluation
    Neal
  • The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development
    Eng
  • The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck
    Mehra
  • Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab
    Moon
  • Cetuximab: from bench to bedside
    Vincenzi
  • Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer
    Wong
  • EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
    Pirker
  • Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study
    Pirker
  • Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study
    O'Byrne
  • Reproducibility of immunohistochemical scoring for epidermal growth factor receptor expression in non-small cell lung cancer [published online ahead of print
    Ruschoff
  • Verifying the role of surgical pathologists in the precision medicine of lung cancer [published online ahead of print
    Cagle
  • EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment
    Brugger
  • A new generation of EGFR tyrosine-kinase inhibitors in NSCLC
    Hirsch
  • Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC)
    Langer
  • Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-lung 2): a phase 2 trial
    Yang
  • Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer
    Ramalingam
  • XL647—a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib
    Pietanza
  • RET, ROS1 and ALK fusions in lung cancer
    Takeuchi
  • Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer
    Yasuda
  • ROS1 rearrangements in lung cancer: a new genomic subset of lung adenocarcinoma
    Janne
  • Brief report: a phase II “window-of-opportunity” frontline study of the mTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study
    Reungwetwattana
  • The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo
    Xu
  • Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells
    Zito
  • The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells
    Zou
  • Tsao MS. c-MET as a potential therapeutic target and biomarker in cancer
    Sierra
  • Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer
    Scagliotti
  • Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer
    Sequist
  • Expression of activated and latent signal transducer and activator of transcription 3 in 303 non-small cell lung carcinomas and 44 malignant mesotheliomas: possible role for chemotherapeutic intervention
    Achcar Rde O, Cagle PT, Jagirdar J
  • Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules
    Shimokawa
  • Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts
    Zhang
  • Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells
    Tanizaki
  • MEK/MAPK inhibitors
    Dy
  • A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer
    Haura
  • KIF5B-RET fusions in lung adenocarcinoma
    Kohno
  • A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing
    Ju
  • The use of single-agent dasatinib in molecularly unselected non-small-cell lung cancer patients
    Kruser
  • Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib
    Johnson
  • K-ras as a target for lung cancer therapy
    Adjei
  • Cancer Genome Atlas Research Network
  • Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy
    Drilon
  • Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component
    Paik
  • Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities
    Perez-Moreno
  • Dual inhibition of EGFR and mTOR pathways in small cell lung cancer
    Schmid
  • Small cell lung cancer
    Sher
  • Phase II study of everolimus (RAD001) in previously treated small cell lung cancer
    Tarhini
  • Demonstration of the stem cell nature of clonogenic tumor cells from lung cancer patients
    Carney
  • Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy
    Shien